Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results

Last Modified: 8/7/2007 First Published: 10/1/2002


1.		Phase III Randomized Study of Etanercept for the Treatment of Cancer-Related Cachexia and Anorexia in Patients With Advanced Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI				NCCTG-N00C1 NCI-P02-0232, N00C1, NCT00046904

Last Modified: 8/3/2006 First Published: 9/25/2004


2.		Phase I/II Pilot Study of Arsenic Trioxide and Etanercept in Patients With Intermediate-2 or High-Risk or Refractory Intermediate-1 or Low-Risk Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				FHCRC-1888.00 NCT00093366

Last Modified: 5/28/2008 First Published: 6/25/2005


3.		Phase I/II Study of Azacitidine and Etanercept in Patients With Intermediate-2- or High-Risk or Refractory Intermediate-1- or Low-Risk Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				FHCRC-1926.00 5967, PHARMION-FHCRC-1926.00, NCT00118287


4.		Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				OSU-0113 NCT00201682


5.		Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				OSU-0041 NCT00201838

Last Modified: 7/12/2007 First Published: 6/1/2000


6.		Phase II Study of Anti-Thymocyte Globulin and Tumor Necrosis Factor Receptor IgG Chimera in Patients With Myelodysplastic Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Any age				NCI				FHCRC-1478.00 NCI-G00-1793, NCT00005853

Last Modified: 12/20/2007 First Published: 9/16/2005


7.		Phase II Study of Anti-Thymocyte Globulin and Etanercept in Patients With Low- or Intermediate-1-Risk Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				FHCRC-1872.00 5740, NCT00217386


8.		Treatment for Acute Graft-Versus-Host Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Closed				10 and over				NCI, NHLBI				285 BMT CTN 0302, U01 HL069294-05, NCT00224874

Last Modified: 1/1/1994


9.		Phase I Multipart Study of High-Dose IL-2 in Combination with the TNF Receptor IgG Chimera TNFR:Fc in Patients with Advanced Malignancies (Summary Last Modified 01/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over								NEMCH-B93-0007 NCI-B93-0007, B93-0007

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute